sPLA2 inhibitor 1
sPLA2 inhibitor 1 structure
|
Common Name | sPLA2 inhibitor 1 | ||
|---|---|---|---|---|
| CAS Number | 393569-31-8 | Molecular Weight | 487.63 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 720.9±60.0 °C at 760 mmHg | |
| Molecular Formula | C31H37NO4 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 389.8±32.9 °C | |
|
Inhibitors of secretory phospholipase A2 group IIA.
Curr. Med. Chem. 12(25) , 3011-26, (2005) Phospholipases A2 cleave membrane phospholipids to release arachidonic acid, the precursor to a large family of pro-inflammatory eicosanoids including prostaglandins and leukotrienes that have been proven to exacerbate numerous diseases that have an inflammat... |
|
|
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats.
J. Immunol. 176(11) , 7000-7, (2006) The development of fibrosis in the chronically hypertensive heart is associated with infiltration of inflammatory cells and cardiac hypertrophy. In this study, an inhibitor of the proinflammatory enzyme, group IIA human secretory phospholipase A2 (sPLA2-IIA),... |
|
|
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
J. Thorac. Cardiovasc. Surg. 144(6) , 1479-85, (2012) There are currently no targeted therapies against lung tumors with oncogenic K-ras mutations that are found in 25% to -40% of lung cancers and are characterized by their resistance to epidermal growth factor receptor inhibitors. The isozyme group IIa secretor... |
|
|
Differential expression of sPLA2 following spinal cord injury and a functional role for sPLA2-IIA in mediating oligodendrocyte death.
Glia 57 , 1521-37, (2009) After the initial mechanical insult of spinal cord injury (SCI), secondary mediators propagate a massive loss of oligodendrocytes. We previously showed that following SCI both the total phospholipase activity and cytosolic PLA(2)-IV alpha protein expression i... |
|
|
Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells.
Anticancer Res. 32(9) , 3601-7, (2012) Group IIa secretory phospholipase A2 (sPLA2 IIa) has been implicated in the regulation of metastasis of non-small cell lung cancer (NSCLC) and the present study investigates its contribution to lung cancer growth and progression. PLA2s initiate signaling in s... |
|
|
Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.
Arthritis. Res. Ther. 11 , R138, (2009) Secretory phospholipase A2 (sPLA2) and matrix metalloproteinase (MMP) inhibitors are potent modulators of inflammation with therapeutic potential, but have limited efficacy in rheumatoid arthritis (RA). The objective of this study was to understand the inhibi... |
|
|
Inhibition of sPLA₂-IIA prevents LPS-induced neuroinflammation by suppressing ERK1/2-cPLA₂α pathway in mice cerebral cortex.
PLoS ONE 8 , e77909, (2013) Neuroinflammation is involved in various central nervous system (CNS) disorders, including brain infections, ischemia, trauma, stroke, and degenerative CNS diseases. In the CNS inflammation, secretory phospholipase A₂-IIA (sPLA₂-IIA) acts as a mediator, resul... |